Johnson & Johnson (JNJ) Interest & Investment Income (2009 - 2026)
Johnson & Johnson (JNJ) posted Interest & Investment Income of $229.0 million for Q1 2026, down 3.38% sequentially from $237.0 million in Q4 2025, and down 31.02% YoY from $332.0 million in Q1 2025.
Johnson & Johnson (JNJ) Interest & Investment Income (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Interest & Investment Income data on file, last reported at $229.0 million in Q1 2026.
- Quarterly Interest & Investment Income fell 31.02% year-over-year to $229.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $953.0 million (down 26.69% YoY) and the FY2025 annual result came in at $1.1 billion, down 20.72% from the prior year.
- Interest & Investment Income slipped to $229.0 million in Q1 2026 per JNJ's latest filing, from $237.0 million in the prior quarter.
- The five-year high for Interest & Investment Income was $450.0 million in Q1 2023, with the low at $22.0 million in Q2 2022.
- Average Interest & Investment Income over 5 years is $268.5 million, with a median of $281.0 million recorded in 2024.
- Year-over-year, Interest & Investment Income soared 1053.85% in 2022 and sank 34.18% in 2025.
- Johnson & Johnson's Interest & Investment Income stood at $150.0 million in 2022, then soared by 142.0% to $363.0 million in 2023, then retreated by 22.59% to $281.0 million in 2024, then fell by 15.66% to $237.0 million in 2025, then fell by 3.38% to $229.0 million in 2026.
- Business Quant data shows JNJ's Interest & Investment Income at $229.0 million in Q1 2026, $237.0 million in Q4 2025, and $227.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 229.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -645.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 73.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 229.00 Mn |
| Dec 28, 2025 | 237.00 Mn |
| Sep 28, 2025 | 227.00 Mn |
| Jun 29, 2025 | 260.00 Mn |
| Mar 30, 2025 | 332.00 Mn |
| Dec 29, 2024 | 281.00 Mn |
| Sep 29, 2024 | 292.00 Mn |
| Jun 30, 2024 | 395.00 Mn |
| Mar 31, 2024 | 364.00 Mn |
| Dec 31, 2023 | 363.00 Mn |
| Oct 1, 2023 | 374.00 Mn |
| Jul 2, 2023 | 326.00 Mn |
| Apr 2, 2023 | 198.00 Mn |
| Jan 1, 2023 | 450.00 Mn |
| Oct 2, 2022 | 150.00 Mn |
| Jul 3, 2022 | 64.00 Mn |
| Apr 3, 2022 | 22.00 Mn |
| Oct 3, 2021 | 13.00 Mn |
| Jul 4, 2021 | 12.00 Mn |
| Apr 4, 2021 | 15.00 Mn |